Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch
- PMID: 37849619
- PMCID: PMC10577434
- DOI: 10.3389/fnmol.2023.1272230
Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch
Abstract
Similar to chronic pain, chronic itch is frequently linked to neural sensitization, a phenomenon wherein the nervous system becomes hypersensitive to stimuli. This process of neural sensitization of chronic itch is orchestrated by various signaling pathways and mediators in both the peripheral and central nervous systems. At the level of the peripheral nervous system, inflammation and neuroimmune interactions induce plastic changes to peripheral nerve fibers, thereby amplifying the transmission of itch signaling. Neural sensitization in the central nervous system occurs at both the spinal cord and brain levels. At the level of the spinal cord, it involves hyperactivity of itch-activating spinal pathways, dysfunction of spinal inhibitory circuits, and attenuation of descending supraspinal inhibitory pathways. In the brain, neural sensitization manifests as structural and functional changes to itch-associated brain areas and networks. Currently, we have a diverse array of neuroimmune-modulating therapies targeting itch neural sensitization mechanisms to help with providing relief to patients with chronic itch. Itch research is a dynamic and continually evolving field, and as we grow in our understanding of chronic itch mechanisms, so will our therapeutic toolbox. Further studies exploring the peripheral and central neural sensitization mechanisms in the context of chronic itch are needed.
Keywords: brain; central; chronic; itch; nervous system; neural sensitization; peripheral; pruritus.
Copyright © 2023 Mahmoud, Oladipo, Mahmoud and Yosipovitch.
Conflict of interest statement
GY serves as an advisory board member for Abbvie, Arcutis, BMS, Cara Therapeutics, GSK, Escient Health, Eli Lilly, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, TreviTherapeutics, and Vifor. GY receives grants/research funding from Eli Lilly, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex. GY is an investigator for Regeneron Pharmaceuticals, Inc., and Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms?Pulm Pharmacol Ther. 2015 Dec;35:81-6. doi: 10.1016/j.pupt.2015.09.001. Epub 2015 Sep 6. Pulm Pharmacol Ther. 2015. PMID: 26351759 Free PMC article. Review.
-
New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?Pflugers Arch. 2013 Dec;465(12):1671-85. doi: 10.1007/s00424-013-1284-2. Epub 2013 May 1. Pflugers Arch. 2013. PMID: 23636773 Free PMC article. Review.
-
Central Mechanisms of Itch.Curr Probl Dermatol. 2016;50:11-7. doi: 10.1159/000446011. Epub 2016 Aug 23. Curr Probl Dermatol. 2016. PMID: 27578065 Free PMC article. Review.
-
Neuroimmune communication regulating pruritus in atopic dermatitis.J Allergy Clin Immunol. 2022 Jun;149(6):1875-1898. doi: 10.1016/j.jaci.2022.03.010. Epub 2022 Mar 23. J Allergy Clin Immunol. 2022. PMID: 35337846
-
Identification of a Spinal Circuit for Mechanical and Persistent Spontaneous Itch.Neuron. 2019 Sep 25;103(6):1135-1149.e6. doi: 10.1016/j.neuron.2019.06.016. Epub 2019 Jul 16. Neuron. 2019. PMID: 31324538 Free PMC article.
Cited by
-
Comparison Between Pregabalin and Sertraline in the Treatment of Uremic Pruritus in Patients With Maintenance Hemodialysis.Cureus. 2024 Jul 30;16(7):e65788. doi: 10.7759/cureus.65788. eCollection 2024 Jul. Cureus. 2024. PMID: 39211714 Free PMC article.
-
Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care.Plants (Basel). 2024 Dec 16;13(24):3515. doi: 10.3390/plants13243515. Plants (Basel). 2024. PMID: 39771213 Free PMC article. Review.
-
Pruritus and Neuropsychiatric Symptoms Among Patients with Darier Disease-An Overlooked and Interconnected Challenge.J Clin Med. 2025 Mar 8;14(6):1818. doi: 10.3390/jcm14061818. J Clin Med. 2025. PMID: 40142630 Free PMC article.
-
Comparative Efficacy and Safety of Tralokinumab and Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Narrative Review.J Clin Med. 2025 Jul 13;14(14):4960. doi: 10.3390/jcm14144960. J Clin Med. 2025. PMID: 40725651 Free PMC article. Review.
-
Whole Body Cryostimulation: A New Adjuvant Treatment in Central Sensitization Syndromes? An Expert Opinion.Healthcare (Basel). 2024 Feb 25;12(5):546. doi: 10.3390/healthcare12050546. Healthcare (Basel). 2024. PMID: 38470657 Free PMC article.
References
-
- Agelopoulos K., Renkhold L., Wiegmann H., Dugas M., Süer A., Zeidler C., et al. . (2023). Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus. J. Invest. Dermatol. 143, 264.e3–272.e3. doi: 10.1016/j.jid.2022.08.042, PMID: - DOI - PubMed
-
- Ariëns L. F. M., van der Schaft J., Bakker D. S., Balak D., Romeijn M. L. E., Kouwenhoven T., et al. . (2020). Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 75, 116–126. doi: 10.1111/all.14080, PMID: - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials